MAIA Biotechnology (MAIA) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 14.1% versus a loss of 47.4%. MAIA Biotechnology is the larger company by market cap ($67.9 million vs $66.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | ZYBT |
|---|---|---|
| Share price | $1.10 | $1.40 |
| Market cap | $67.92M | $66.35M |
| 1-day change | -1.79% | -6.67% |
| YTD return | -28.10% | +21.74% |
| 1-year return | -14.06% | -47.37% |
| Forward P/E | 0.99 | — |
| EPS (TTM) | $-0.62 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.64M |
| Revenue growth (YoY) | — | -34.83% |
| Net income (latest FY) | $-22.40M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | — | -60.60% |
| Net margin | — | -59.99% |
| 52-week high | $3.19 | $8.01 |
| 52-week low | $0.87 | $0.616 |
| Distance from 52-week high | -65.52% | -82.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +990.91% | — |
| Average volume | 481.94K | 5.64M |
| Shares outstanding | 61.74M | 47.39M |
| Employees | 13 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed ZYBT by 33.3 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
MAIA vs ZYBT FAQ
Which is bigger, MAIA Biotechnology or Zhengye Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $67.92M compared with $66.35M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, MAIA or ZYBT?
MAIA returned -14.06% over the past 12 months, compared with -47.37% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.